Pharma major Lupin Limited
(Lupin) announced that it has received approval for its Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie, Inc’s (AbbVie) AndroGel 1.62%.
Lupin’s Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie’s AndroGel, 1.62%. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone:
Primary hypogonadism (congenital or acquired) and
Hypogonadotropic hypogonadism (congenital or acquired)
Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), (RLD: AndroGel) had annual sales of approximately $893mn in the US (IQVIA MAT December 2018).
Lupin Ltd is currently trading at Rs807.35, up by Rs3.4 or 0.42%, from its previous close of Rs803.95 on the BSE.
The scrip opened at Rs805.05 and has touched a high and low of Rs812 and Rs803.25, respectively. So far 4,97,167 (NSE+BSE) shares have been traded on the counter. The current market cap of the company is Rs36,378.23cr.